Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.

MLA

Chaudhuri, K.Ray, et al. “Opicapone versus Placebo in the Treatment of Parkinson’s Disease Patients with End-of-Dose Motor Fluctuation-Associated Pain: Rationale and Design of the Randomised, Double-Blind OCEAN (OpiCapone Effect on Motor Fluctuations and PAiN) Trial.” BMC Neurology, vol. 22, no. 1, Mar. 2022, pp. 1–12. EBSCOhost, https://doi.org/10.1186/s12883-022-02602-8.

APA

Chaudhuri, K. R., Odin, P., Ferreira, J. J., Antonini, A., Rascol, O., Kurtis, M. M., Storch, A., Bannister, K., Soares-da-Silva, P., Costa, R., Magalhães, D., & Rocha, J. F. (2022). Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial. BMC Neurology, 22(1), 1–12. https://doi.org/10.1186/s12883-022-02602-8

Chicago

Chaudhuri, K. Ray, Per Odin, Joaquim J. Ferreira, Angelo Antonini, Olivier Rascol, Mónica M. Kurtis, Alexander Storch, et al. 2022. “Opicapone versus Placebo in the Treatment of Parkinson’s Disease Patients with End-of-Dose Motor Fluctuation-Associated Pain: Rationale and Design of the Randomised, Double-Blind OCEAN (OpiCapone Effect on Motor Fluctuations and PAiN) Trial.” BMC Neurology 22 (1): 1–12. doi:10.1186/s12883-022-02602-8.